Ignis Therapeutics
Series A in 2021
Ignis Therapeutics is a life science company developing innovative therapies in the field of the central nervous system. With a strong commitment to self-discovery and a development strategy to advance the treatment paradigm, Ignis Therapeutics transforms the approach to treating CNS conditions. Ignis Therapeutics is dedicated to developing products that significantly improve the lives of patients while also providing additional therapeutic options for physicians.
Beijing Haoxinqing Mobile Healthcare Technology Co., Ltd. is a Chinese company that operates an online medical service platform. The platform specializes in mental psychology and chronic disease management, offering users remote diagnosis and treatment services. By facilitating access to medical care, Haoxinqing enables patients to conveniently obtain necessary healthcare services, addressing both mental health needs and the ongoing management of chronic conditions.
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Lyvgen is a biopharmaceutical company based in Shanghai, China, focused on immuno-oncology research and development. Established in 2016, the company specializes in the creation of antibody-based therapeutics, notably the PD-1 antibody SSI-361, along with a proprietary set of co-stimulation agonist antibodies. These products aim to activate specific receptors in the tumor microenvironment, enhancing the immune response against cancer while minimizing adverse effects on healthy tissues. Through its innovative approach, Lyvgen is dedicated to advancing cancer immunotherapy, with the goal of improving long-term survival rates for patients.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality. MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality. MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development.
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.
Beijing Haoxinqing Mobile Healthcare Technology Co., Ltd. is a Chinese company that operates an online medical service platform. The platform specializes in mental psychology and chronic disease management, offering users remote diagnosis and treatment services. By facilitating access to medical care, Haoxinqing enables patients to conveniently obtain necessary healthcare services, addressing both mental health needs and the ongoing management of chronic conditions.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established in February 2013 and is affiliated to Oriental Science and Technology Holding Group Co., Ltd. (hereinafter referred to as “Oriental Instrument”), a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. It is headquartered in Yizhuang Economic and Technological Development Zone, Beijing. . Since the establishment of Guoke Hengtai for 4 years, the company has experienced two rounds of investment in A and B, and its performance has continued to grow at a high speed, with a compound annual growth rate of over 50%. In 2017, the company officially launched the IPO listing journey.
Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in manufacturing reagents for tissue imaging and multiplexing detection, primarily serving the life science and biomedical research communities. Ultivue offers advanced technologies such as DNA-PAINT and DNA-Exchange, which facilitate the collection of high-resolution microscopic images. These innovations are aimed at enhancing the understanding of biological processes and medical diagnostics. The company’s products are designed for use in fluorescent microscopy-based research and are expected to have future applications in clinical diagnostics.
Neuspera Medical Inc. specializes in the development and manufacture of ultra-miniaturized implantable devices designed for neuromodulation therapy, often referred to as "electroceuticals." Utilizing licensed mid-field powering technology, these devices leverage the body as a natural waveguide to deliver energy effectively. Founded in 2013 and based in San Jose, California, Neuspera aims to enhance the quality of life for patients dealing with chronic illnesses by providing less invasive and adaptable treatment options. The company's innovative approach allows for deeper implantation of its devices, offering patients new possibilities in managing their health conditions.
HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.
HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.
Halda Therapeutics
Series A in 2019
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.
Developer of bi-targeting new drug development technology designed to promote the development of drugs treating oncology and chronic diseases. The company's technology includes its proprietary bi-targeting drug conjugation (XDC) technology platform, like its BEST™ Platform, C-PROTAC Platform and Chronic Diseases Platform, enabling patients to have innovative drugs to treat multiple chronic diseases by tissue/organ site-specific targeting.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Another key candidate, FTX-6058, aims to increase fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. In addition to these programs, Fulcrum is exploring drug targets for other conditions such as Duchenne muscular dystrophy, Friedreich ataxia, myotonic dystrophy 1, and various neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma and MyoKardia to advance research and develop targeted therapies for pulmonary diseases and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum Therapeutics is committed to improving the lives of patients facing significant health challenges.
GloriousMed Technology is a Healthcare company.
Curon Biopharma is focused on developing drugs for immuno-oncology therapies. The company offers a range of innovative cancer immunotherapeutic agents aimed at overcoming the limitations of existing cancer treatment approaches. By providing advanced immunotherapies, Curon Biopharma enables physicians to enhance treatment options for their patients battling cancer.
Lyvgen is a biopharmaceutical company based in Shanghai, China, focused on immuno-oncology research and development. Established in 2016, the company specializes in the creation of antibody-based therapeutics, notably the PD-1 antibody SSI-361, along with a proprietary set of co-stimulation agonist antibodies. These products aim to activate specific receptors in the tumor microenvironment, enhancing the immune response against cancer while minimizing adverse effects on healthy tissues. Through its innovative approach, Lyvgen is dedicated to advancing cancer immunotherapy, with the goal of improving long-term survival rates for patients.
ITeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for cancer treatment. Founded in 2011 and headquartered in Gosselies, Belgium, with operational ties to Cambridge, Massachusetts, the company leverages its expertise in tumor immunology to create small molecule immunomodulators. Its product pipeline includes EOS-850, an antagonist of the adenosine A2a receptor, currently in an open-label Phase 1/2a clinical trial for adult patients, and EOS-448, which targets the TIGIT receptor and is also in a Phase 1/2a clinical trial. ITeos aims to enhance the effectiveness of cancer therapies by targeting resistance mechanisms within the tumor microenvironment, thereby improving the clinical outcomes of existing treatment modalities and newer immunotherapies.
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Yiyao is also knwon as 111.com.cn. Yiyao is an online drug superstore where patients can buy over-the-counter medications, traditional Chinese remedies, and a variety of other health products including everything from sex toys to diet pills. 111.com.cn operates as an online portal for selling pharmaceutical products.
Shenzhen Kangtai Biological Products Co., Ltd. is a listed company integrating research, development, production and sales of biological products.the company has R&D centers and industrial bases in Shenzhen and Beijing. It is one of the major hepatitis B vaccine manufacturers in China.The company's main business is the development, production and sales of human vaccines. The product categories cover Class I and Class II vaccines. The main products are recombinant hepatitis B vaccine (Saccharomyces cerevisiae), Haemophilus influenzae type b conjugate vaccine, and measles and rubella. Live attenuated vaccine, cell-free white-breaking Haemophilus influenzae type b combined vaccine, 23- valent pneumococcal polysaccharide vaccine and other products.
Forerunner Medical (Shanghai) Co., Ltd. develops and manufactures medical devices for minimally invasive treatment. It primarily develops and produces low-temperature plasma radiofrequency generators and electrodes for sport medicine, disk demo-pression, and ENT treatment applications. Its products include plasma radiofrequency systems; and electrodes for joint, spine, cervical, lumbar, transforaminal endoscopic operation, and ENT treatment applications. The company was founded in 2009 and is based in Shanghai, China.
Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on developing treatments for severe inflammation and autoimmune diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, aimed at treating conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. The company is also advancing additional candidates, including VIB4920 for kidney transplantation rejection and Sjögren’s syndrome, as well as VIB7734 for cutaneous lupus erythematosus. Viela Bio has formed a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, the company is dedicated to addressing unmet medical needs in the field of autoimmune disorders.
Engine Biosciences Pte. Ltd. is a biotechnology company that specializes in drug discovery by leveraging machine learning and genomics. Founded in 2014 and based in Singapore, the company has developed a validated platform that integrates high-throughput wet lab experimentation with artificial intelligence algorithms. This unique approach enables the mapping and analysis of complex biological networks and gene interactions, facilitating the identification of disease-driving errors. The platform supports researchers and drug developers in various aspects of drug discovery, including target discovery, drug repositioning, and pathway analysis. Engine Biosciences collaborates with American Fortune 500 companies and research institutions, aiming to accelerate and reduce the costs associated with the research and development process for new medical therapies. The company’s leadership team includes experts from renowned institutions such as MIT, Harvard, Mayo Clinic, and UCSD.
Neuspera Medical Inc. specializes in the development and manufacture of ultra-miniaturized implantable devices designed for neuromodulation therapy, often referred to as "electroceuticals." Utilizing licensed mid-field powering technology, these devices leverage the body as a natural waveguide to deliver energy effectively. Founded in 2013 and based in San Jose, California, Neuspera aims to enhance the quality of life for patients dealing with chronic illnesses by providing less invasive and adaptable treatment options. The company's innovative approach allows for deeper implantation of its devices, offering patients new possibilities in managing their health conditions.
Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in manufacturing reagents for tissue imaging and multiplexing detection, primarily serving the life science and biomedical research communities. Ultivue offers advanced technologies such as DNA-PAINT and DNA-Exchange, which facilitate the collection of high-resolution microscopic images. These innovations are aimed at enhancing the understanding of biological processes and medical diagnostics. The company’s products are designed for use in fluorescent microscopy-based research and are expected to have future applications in clinical diagnostics.
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing innovative cell therapies for cancer treatment. The company's lead product candidates include GC012F, a dual-targeted CAR-T therapy for multiple myeloma currently in Phase I trials; GC019F, which targets adult B cell acute lymphoblastic leukemia and is also in Phase I trials; and GC007F, aimed at B cell non-Hodgkin’s lymphoma, also in Phase I. Additionally, Gracell is developing GC027, a CAR-T candidate targeting adult T cell acute lymphoblastic leukemia, and GC007g, an allogeneic CAR-T therapy for relapsed or refractory B-ALL, both in Phase I trials. Beyond these, Gracell has a pipeline of earlier-stage product candidates targeting various cancers, including ovarian and breast cancer. Founded in 2017, Gracell Biotechnologies is committed to advancing cellular therapeutics to improve patient outcomes in hematological malignancies and solid tumors.
Medeor Therapeutics, Inc. specializes in the research, development, and commercialization of personalized cellular immunotherapies aimed at enhancing outcomes for organ transplant recipients. The company focuses on creating innovative cellular immunotherapy products, particularly for kidney transplant patients, under the MDR-10X brand. By employing advanced approaches to organ transplant immune tolerance and immuno-oncology, Medeor Therapeutics seeks to improve kidney function and reduce the risk of graft rejection more effectively than traditional immunosuppressive medications. Founded in 2012, the company is headquartered in San Mateo, California.
AnchorDx is a company focused on advancing precision medicine through its development of next-generation sequencing techniques, particularly utilizing molecular liquid biopsies. This approach offers non-invasive access to genetic information, enabling patients to gain insights into their physiological conditions and prepare for potential future health issues. With a core team boasting over 20 years of experience in cancer genomics, genetics, and bioinformatics, AnchorDx aims to establish itself as a leading global provider of precision medical solutions. The company collaborates with various middle and downstream enterprises, fostering a comprehensive industrial chain that spans from academic research to clinical product transformation. Additionally, AnchorDx has formed partnerships with numerous large-scale third-party inspection agencies, hospitals, and research institutes, contributing to the development of independent intellectual property rights and competitive clinical testing products that deliver accurate and comprehensive services to patients, doctors, and medical institutions.
Helian Health, established in 2014 and based in Hangzhou, China, specializes in providing Wi-Fi services to hospitals and developing online healthcare platforms that cater to both patients and healthcare professionals. The company has created several applications, such as Xiaohe Yizhu, which enables healthcare providers to store health records in the cloud and share medical case studies, and Hejiankang, designed for companies to offer personalized health recommendations to their employees. Helian Health has built a substantial platform serving over 1,700 hospitals across 245 cities, including many top-tier hospitals, and has achieved a significant presence in the medical Internet of Things (IoT) sector. The company also collaborates with equipment manufacturers to implement IoT solutions that enhance hospital operations, thereby improving service efficiency and reducing costs. Through its commitment to creating comprehensive health services, Helian Health aims to leverage technology to promote healthier living and contribute to the advancement of medical care.
"Suzhou Jiecheng Medical Technology Co., Ltd." is a high-tech medical technology company with completely independent intellectual property rights and its patented technology is in a leading position in the world. The company was established in September 2009. The R&D team consists of Cardiologist Zhang Ji and several domestic and foreign R&D experts. The company's leading project is the development and production of the innovative "J-Valve Precision Positioning Heart Valve Implant System" technology. "J-Valve Precise Positioning Heart Valve Implant System" is a minimally invasive surgical technique that eliminates the need to open a chest and eliminates extracorporeal blood circulation. It can significantly reduce patient's surgical trauma, shorten postoperative recovery time, reduce patient's pain, and reduce The requirements of the patient's physical condition, thereby expanding the range of application of the disease, improving the efficacy of treatment, reducing the cost of surgery, so that the majority of patients need to replace the heart valve can be treated. Other similar products can only be implanted into the heart through the use of imaging technology. The J-Valve system can completely rely on its own positioning device to assist doctors in performing valve replacement surgery, thereby reducing the risk of surgery, easier to operate and master, and simplifying the heart valve Replacement process. The above advantages will help reduce the overall cost of the country's health care system, promote the reform of the health care system, reduce medical costs, and save social medical resources. At the same time, drastic changes in the long-term dependence on